Epigral Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/a4xtnayb4u6ekqk07ywq73xj.pdf

Key Takeaways


The Realization Super-Cycle & Margin Peak

Maulik Patel: "I believe that in coming times irrespective of anything there is no possibility to reach back to original level of FY2021 or the first quarter of FY2022 so there is a possibility it might go down little bit, but I do not think so it will come back to original level of FY2021 or Q1 of FY2022."

The Derivative-Led Growth Pivot

Maulik Patel: "Currently the ECH is in peak demand due to the infrastructure projects are going on all over the world and the demand has picked up after the COVID situation... we continue to believe that it will remain the same for next I think next one or two years' time."

FY23 Guidance: Volume, Value & the Mix Shift

Milind Kotecha: "...the products that we are getting into ECH and CPVC they are high value products because of which we are at least visibly confident enough to reach to have a 50% growth on the current FY2023 so that reaches around 2250 of revenue."

Integration as Competitive Moat

Maulik Patel: "Caustic soda is never going to be issue in the world because right now it is short supply and people are doing the net export from the country like India, so again challenge with all the Chlor-Alkali player will be how they are integrated, how they will consume chlorine and hydrogen, I think you must have noticed that we are coming with epichlorohydrin and the chlorinated PVC plant, which will consume chlorine, which is coming out from our expansion of a caustic soda plant, so we are well integrated so we are better off we feel that in the coming times once we commission caustic soda along with both the derivatives together."

Balance Sheet & Capital Allocation

Sanjay Jain: "Our debt has increased to a highest level of 965 Crores in FY2022, but this is a peak level."

Guidance & Commitments

CommitmentSpecificsTimeline
FY23 revenue growth20–22% volume growth, 50% value growth (~₹2,250 Cr)FY23
ECH plant commissioningFull-fledged commissioning, trial runs from May 15, 2022End of May / early June 2022
CPVC plant commissioningCommissioningEarly Q2 FY23
ECH capacity ramp~40–50% utilization initially, gradual increase from Q3 onwardQ2 FY23 → Q3 FY23
Long-term EBITDA margin28% ±2% (range 26–30%)Long-term
Debt-to-EBITDA guardrailRemain below 2xOngoing
Annual debt repayment~₹140–150 Cr per yearFY23 and beyond
Five-year revenue target₹5,000 Cr, 25% CAGR from FY22 baseBy FY27
Chlorotoluene project capex~₹180 Cr, funded through internal accrualsSpend split across FY23 and FY24

Key Metrics

MetricQ4 FY22
Revenue₹499 cr, up 93% YoY
EBITDA₹175 cr, up 118% YoY
EBITDA margin35%, highest level
PAT₹99 cr, up 202% YoY
PAT margin20%
FY22 revenue₹1,551 cr, up 87% YoY
FY22 PAT₹253 cr, up 2.5x YoY
FY22 EBITDA margin33%
FY22 volume growth20%
FY23 value growth guidance50%
FY23 volume growth guidance20%
Five-year revenue target₹5,000 cr by FY27, CAGR 25%
Caustic soda ECU realization₹49,300, up from ₹45,800 in Q3
Overall plant utilization87% in FY22, improved 6% vs FY21
Hydrogen peroxide utilization78% in FY22 vs 57% in FY21
Debt to EBITDA1.9x vs 2.1x in FY21
Long-term debt₹965 cr peak in FY22
Power cost per unit₹9.15 in Q4 vs ₹7.67 for full FY22
Coal consumption cost~₹9,000 per metric ton in Q4
Exports share5% of total products in FY22